Skip to main content
Premium Trial:

Request an Annual Quote

Luminex, Abbott Strike R&D and Supply Deals

NEW YORK, Jan. 15-Abbott Laboratories will develop and distribute assays and instruments using Luminex's bead-based xMAP technology, the two companies said today.

 

The companies have signed two agreements that grant Abbott the right to license, supply and distribute Luminex biological testing technologies, develop new products, and purchase and distribute existing Luminex products.

 

Luminex will receive an upfront license fee from Abbott and royalties on commercialized assays and instruments. Abbott will also directly purchase Luminex 100 systems and xMAP microspheres.

 

The company's xMAP system, which is based on microsphere analysis, allows for medium- and high-throughput multiplexed assays.

 

Luminex, based in Austin, Tex., is publicly held.

 

For further information, see the company statement.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.